Wortmannin

目录号:S2758 别名: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。也会抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。

规格 价格 库存 购买数量  
RMB 899.84 现货
RMB 1414.71 现货
RMB 2210.53 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。也会抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。
靶点
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
体外研究

钙或肽底物不影响Wortmannin对MLCK的抑制,但高浓度的ATP会减弱此种抑制。Wortmannin直接与MLCK催化结构域相互作用,导致不可逆转的酶活性减弱。Wortmannin对cAMP依赖蛋白激酶,cGMP依赖的蛋白激酶,钙调蛋白依赖激酶II,和蛋白激酶C均无抑制作用。[1] Wortmannin抑制由fMLP诱导的PtdInsP3(磷脂酰肌醇3,4,5-三磷酸化)形成,IC 50为5 nM 。在人中性粒细胞中,Wortmannin剂量为100 nM时可发挥完全抑制作用,增加PtdInsP2水平,且对PtdInsP和 PtdIns没有影响;Wortmannin可动态调控F-actin水平对fMLP刺激的肌动蛋白聚合无影响。[2]在RBL-2H3细胞中,Wortmannin通过结合110-kDa蛋白,不可逆的抑制磷酸肌醇3激酶(PI3-kinase)活性(IC 50为3 nM)对,对Pi4-kinase没有影响。Wortmannin也抑制Fc epsilon RI介导的组胺分泌和白三烯释放,对酪氨酸激酶Lyn无影响。[3]在大鼠脂肪细胞中,剂量为0.1 μM的 Wortmannin可完全抑制胰岛素诱导的己糖吸收,二不影响异丙肾上腺素刺激的脂肪分解活性。[4] 在人脐静脉内皮细胞中,在IGF-1的存在下,Wortmannin抑制胰岛素诱导一氧化氮生产,IC50为500nM。[5]在中国仓鼠卵巢细胞中, Wortmannin以50 μM剂量可抑制DNA双链断裂(DSB)修复,但对DSB水平无影响或单链断裂(SSB)酶活无影响。Wortmannin可加强电离辐射(红外)诱导的细胞毒作用,但本身无毒性。[6] Wortmannin抑制水球样激酶(PLK 1)活性,IC 50为24nM,造成细胞G 2 / M阻滞。[7] 在人巨噬细胞中,Wortmannin增加 Toll样受体(TLR)介导的白细胞介素- 6的积累,EC 50 = 50 nM。在小鼠巨噬细胞中,Wortmannin显着增强TLR诱导一氧化氮合酶(iNOS)的表达和亚硝酸盐积累。Wortmannin激活核因子-κB和上调细胞因子mRNA量。[8] Wortmannin也抑制水球样激酶(PlK)1和PlK 3,在有丝分裂中发挥重要作用。Wortmannin治疗可能导致可减少由DNA损伤诱导的p53丝氨酸20位磷酸化。[9] 在SW 1990细胞中,Wortmannin可抑制透明质酸诱导Akt磷酸化和细胞运动/迁移。[10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 M1PC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn2[2NSOi53IN88US=> NWmxV|BoOS12IHS= M{XoW2ROW09? NUfUR2Rj\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? M1zRPVI2PDlyM{iz
H1703 NV30XGZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T4flIvPSEQvF2= MVSxMVQh\A>? NGTUVVNFVVOR MmjE[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> MVKyOVQ6ODN6Mx?=
HUVECs MVTDfZRwfG:6aXPpeJkhSXO|YYm= M1u3c|ExOCCwTR?= M4nrV|I1KGh? NF3Ec|VifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? M{nIU|I2PDVyMUi2
APRE-19 MnPjRZBweHSxc3nzJGF{e2G7 M2LBRlUh|ryP NYHpZ3dlOjRiaB?= MnnxZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? M3r5PFI2OzJ7NkG3
MDA-MB-231 M2rPbGFxd3C2b4Ppd{BCe3OjeR?= NY\Td25uOcLizszNxsA> M1GwZlQ5KGh? NXnmV3FDTE2VTx?= M1XMcYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEB1emWjdHXkJJdqfGhiMkWg{txOKG:oIF[xJI9zKEZ{INMg MUCyOVMxODl|Mh?=
MCF7 NWLyTJByTnWwY4Tpc44hSXO|YYm= M{LSfVExOCCwTR?= NFTncoozPCCq NID0O|RmdGmvaX7heIV{KEV{LXnu[JVk\WRiQWLFMWx2[yCjY4Tpeol1gQ>? M3TzUlI2OTd{NUW3
HT-29  NHPE[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\vcmRZOS53wrFCuW0> M2D2c|k3KGh? Mn\C[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= NE[xUWIzPTBzMkGyNy=>
MO59K  MnS2R5l1d3SxeHnjbZR6KEG|c3H5 NIPye4w2yqEQvF2= MYS3JIQ> M165V2ROW09? MYrlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NH\2[XgzPDl3M{W2NS=>
MO59J MnzqR5l1d3SxeHnjbZR6KEG|c3H5 NXq1dGl[PcLizszN MXq3JIQ> NEXBO5FFVVOR MVflcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NVfK[5djOjR7NUO1OlE>
MO59K  MknyRZBweHSxc3nzJGF{e2G7 NWHnPJVkOTBizszN NHPB[mkzPCCq NYrV[21sTE2VTx?= NXqwSmpRcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw Ml\rNlQ6PTN3NkG=
MO59J Mln5RZBweHSxc3nzJGF{e2G7 MWqxNEDPxE1? M4nIcFI1KGh? NF60XJVFVVOR MnyxbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv M2TKc|I1QTV|NU[x
HepG2 NHjMPHJHfW6ldHnvckBCe3OjeR?= NFTOUIUyODBibl2= MViwMlUhcA>? Mnr1SG1UVw>? M1PiUIJtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NXLIe4JLOjR6NkOzOVA>
A549  M33Ecmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHr[ow{KML3TdMg M3nJR|IhcA>? NIHFTZN{fXCycnXzd4V{KHCnbXX0doV5\WRvaX7keYNm\CCDa4SgZY5lKEeVS{ROtkBi[3SrdnH0bY9vNCCVLYDoZZNmKGG{cnXzeEwh[2WubDDhdI9xfG:|aYOgZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:w MW[yOFg1Pzh4Mx?=
A549  NVTRSXo4TnWwY4Tpc44hSXO|YYm= MmTiNVDDqM7:bdMg Mne0NVYhcA>? MlHVSG1UVw>? NXeyfYNIdW:mdXzheIV{KHSqZTDJRXYhemWybHnjZZRqd25iYX7kJINifXOnczDy[ZRmdnSrb36gc4YhVlBiaX6geIhmKG63Y3zleZMv MmnJNlQ5ODJzMUG=
SK-N-LO M3P6eGZ2dmO2aX;uJGF{e2G7 MWGxNFAhdk1? MmewNE42KGh? NIfx[Ghl\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? Mlj2NlQ3PTR4ME[=
HL-60 MXTGeY5kfGmxbjDBd5NigQ>? NGXTNFIxNjIEoN88US=> NWnXeohLPzJiaB?= MX3icI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= MWWyOFYxPzJ5Mx?=
HepG2  MY\GeY5kfGmxbjDBd5NigQ>? NWP0XXRVOjByIH7N M{XlUVAvPSCq NGrwXVBifHSnboXheIV{KE[xeF:gdIhwe3Cqb4L5cIF1cW:w MXOyOFU{PTF7Mh?=
H520 M2XGfWZ2dmO2aX;uJGF{e2G7 NV62UnVrOTEEoN88US=> NYm3ZndGOSCq MWTEUXNQ M{\YNoRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> MYOyOFQ1Pzl|NR?=
H1975 NEm4WoxHfW6ldHnvckBCe3OjeR?= NYnNdWZ[OTEEoN88US=> M{HBe|EhcA>? NEO2enJFVVOR M2fzdIRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> NVz4bmNQOjR2NEe5N|U>
MG-63 M3i0RmFxd3C2b4Ppd{BCe3OjeR?= M2TkcFExKML3TR?= M33JcVEzKGh? NHTrS|BmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? MmXMNlQ{PTh|MEG=
5637 MmPLRZBweHSxc3nzJGF{e2G7 MVWxNOKh|ryP M2XaelQxKG2rbh?= MY\y[ZZmenOnczDwNlFYSUZzIHX4dJJme3Orb36sJGNFUyCneIDy[ZN{cW:wLDDhcoQh[2WubDDpcohq[mm2aX;uJIlv\HWlZXSgZpkh\nWlb3nkZY4> MmLwNlQ{OzN6Nki=
HEK-293 MWfGeY5kfGmxbjDBd5NigQ>? MVexOVBvVQ>? MlfsNVYhcA>? MnfxSG1UVw>? NHTrbXhl\WO{ZXHz[ZMhS1KWIHHjeIl3cXS7 MnvRNlQ{OjR|Nk[=
SW480  M4P1[GZ2dmO2aX;uJGF{e2G7 NULQflFyOTVybl2= NHm2V2ozOCCq NEXCeIVFVVOR MoDZdoVlfWOnczDj[YxtfWyjcjDhZ4N2dXWuYYTpc44hd2ZizsKtZ4F1\W6rbh?= NGPTTmwzPDN{NEO2Oi=>
HepG2 M{j3bWZ2dmO2aX;uJGF{e2G7 M4TpeFExOCCwTR?= NYexbIxsOjRiaB?= M4fhU4F1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz NIj4TVczPDJ7N{WxNC=>
HCT 116  NYTabpU{TnWwY4Tpc44hSXO|YYm= NGjwfYUyODBibl2= MlzLNlQhcA>? NV25PXNL[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NF3HNJYzPDJ7N{WxNC=>
BEL/FU MoTVSpVv[3Srb36gRZN{[Xl? Mo\SNUBuVQ>? M1L5SVI1KGh? MVLk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> NIW4OlgzPDJ|MkC5PS=>
Huh7  M2n5eGZ2dmO2aX;uJGF{e2G7 M1n5blPDqM7:TR?= NWLCfm9NOSCq MX3y[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> NWfFS|JEOjRzOESxPVY>
A-375 NWfyeoNnSXCxcITvd4l{KEG|c3H5 M{\QOVQwQCEQvF2= MU[yOEBp MXPlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NU\PPXFCOjRzMUOxO|M>
A-375-TS  MkezRZBweHSxc3nzJGF{e2G7 NUTLSJJqPC96IN88US=> MUiyOEBp M1KxVoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MoHTNlQyOTNzN{O=
Mel-HO MnzlRZBweHSxc3nzJGF{e2G7 MX:0M|gh|ryP M4L5R|I1KGh? NYPBbGF5\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NUKxdJdPOjRzMUOxO|M>
Mel-HO-TS NFfSN2hCeG:ydH;zbZMhSXO|YYm= NW[2SVUzPC96IN88US=> MnnJNlQhcA>? MmXu[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NYfIWHZTOjRzMUOxO|M>
MeWo MmTYRZBweHSxc3nzJGF{e2G7 NIHi[FE1NzhizszN M1LRNFI1KGh? M{HoeYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MUeyOFEyOzF5Mx?=
Mel-2a MlfVRZBweHSxc3nzJGF{e2G7 NIjDTIY1NzhizszN MVyyOEBp NXr3e49[\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M1G3elI1OTF|MUez
MDA-MB-231 MmH6SpVv[3Srb36gRZN{[Xl? MYew5qCUPDByIH7N MXG0JIg> MVnzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIHZOXgzOjlyNkK1PS=>
MDA-MB-231 MX\GeY5kfGmxbjDBd5NigQ>? MoLFOFAxKG6P NFTuR4o1KGh? M2K0eIRm[3KnYYPld{BOVVBvOTDhcoQhUUxvODDwdo91\WmwIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIrCRlkzOjlyNkK1PS=>
Jurkat M3mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZN|AvOjVvMT6yOUDPxE1? M123TFI1NzR6IHi= NGfxNYJFVVOR M3O1WYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NWLVSYF7OTl5NUexPFU>
Namalwa NHixWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfZemgxNjJ3LUGuNlUh|ryP NXTQVmE{OjRxNEigbC=> NEfZ[mNFVVOR NX2zbHhycW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= M4TYbFE6PzV5MUi1
Jurkat MWHBdI9xfG:|aYOgRZN{[Xl? Moi0NE4zPS1zLkK1JO69VQ>? M2D3fFI1NzR6IHi= MVvEUXNQ MnT1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MnrkNVk4PTdzOEW=
Namalwa MnrBRZBweHSxc3nzJGF{e2G7 Mn23NE4zPS1zLkK1JO69VQ>? M3q2SVI1NzR6IHi= NIfLWYNFVVOR M4HYT4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> MmX2NVk4PTdzOEW=
K562 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PFXVI1KGh? NGiyUZVKSzVyPUK1xtExNjF2IH7N MVqxPVY3OjN4MR?=
SW1990 NIHjOm5HfW6ldHnvckBCe3OjeR?= MVSwMlAyNTFizszN MUixJIg> NWiweYFjcW6qaXLpeJMhUEFvaX7keYNm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NX30V49UOTl2NkmwNlA>
RT112  NHXoUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW2XIFyOTEEoN88US=> NUPzUWNuOjRiaB?= NYLmc5IxTE2VTx?= MV;k[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gS|IwVSClZXzsdy=> M1PsfFE5Pzh5OEOy
MHG-U1 NXHZNllkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjYR|k2OTEEoN88US=> NFnSU5EzPCCq MYLEUXNQ MlLu[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> M373SlE5Pzh5OEOy
SMMC-7721 M3TNdGFxd3C2b4Ppd{BCe3OjeR?= NVG2e3U1OjBywrDuUS=> MXiyOEBp NUO0ZoQxcW6lcnXhd4V{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?= NIrzOYYyPzV3N{G5NS=>
SMMC-7721 NYqxbWdOTnWwY4Tpc44hSXO|YYm= NV3JbIg4OjBywrDuUS=> M{Lt[FI1KGh? M4j0dpVxNXKnZ4XsZZRmeyEQskGsOGdVOSCneIDy[ZN{cW:w M{TUV|E4PTV5MUmx
HeLa MnnuSpVv[3Srb36gRZN{[Xl? MUmxNFDDqG6PwrC= NYO5XmJHOSCq MVHhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= MXqxOlg6ODlzNR?=
MRC5VI MUXGeY5kfGmxbjDBd5NigQ>? MoPZNVIvPSCvTR?= M1\SOlAvPSCq M1PnSGROW09? MWDhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> MmjjNVYzOjd|OUS=
AT5BIVA Mm\2SpVv[3Srb36gRZN{[Xl? NGnmWI4yOi53IH3N MoXWNE42KGh? MV;EUXNQ MVrhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NGO0cJUyPjJ{N{O5OC=>
M059J NWXWN2k{TnWwY4Tpc44hSXO|YYm= NHzGcmoyOi53IH3N Mk[4NE42KGh? MonrSG1UVw>? NVTYZWFw[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NFfoZ44yPjJ{N{O5OC=>
HeLa M1rhUGZ2dmO2aX;uJGF{e2G7 MWCxNk42KG2P MoKxNE42KGh? MYDEUXNQ NYi3bJlK[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MoDKNVYzOjd|OUS=
N2a NEe4eI9CeG:ydH;zbZMhSXO|YYm= M1njdFAvOS1zMDFOwG0> M3fDOVIhcA>? MUjpcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M4TKOFE2QDR{N{[3
Jurkat  NGr3eIZMcW6jc3WgRZN{[Xl? MUjJR|UxKG:oIEK0JI5O M4f3eVE2PjZ2NUG5

... Click to View More Cell Line Experimental Data

体内研究 Wortmannin剂量为1mg/kg可抑移植瘤小鼠中SW1990的腹膜转移,无重量损失。[10] Wortmannin抑制在小鼠正常组织(肺,心脏和脑组织匀浆)及肿瘤组织中的phosphatidylinositide 3- B激酶(PKB)/磷酸化Akt,在剂量为0.7 mg/kg时无死亡或急性毒性。与gemcitabine联合使用时,可大大增加细胞凋亡和抑制原位肿瘤生长,两种药物单独使用都无以上效果。[11]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[11]
+ 展开
  • Animal Models: 人胰腺癌细胞 PK1s.c.和原位注入SCID免疫缺陷小鼠。
  • Formulation: 0.4 mg/mL 溶于 DMSO, 使用时用 0.9% NaCl 稀释
  • Dosages: 0.175, 0.35, 和0.7 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
5%DMSO+corn oil
11mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 428.43
化学式

C23H24O8

CAS号 19545-26-7
稳定性 powder
in solvent
别名 KY 12420

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Wortmannin | Wortmannin供应商 | 采购Wortmannin | Wortmannin价格 | Wortmannin生产 | 订购Wortmannin | Wortmannin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID